23 results about "Stroke treatment" patented technology

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

The invention belongs to the technical field of heat stroke treatment, and particularly discloses an application of DNAzyme in preparation of a medicine for treating heat stroke, and the DNAzyme is the DNAzyme for targeted regulation and control of ZBP1 protein expression. The invention further discloses a medicine for preventing and treating heat stroke. The invention has an important value for a prevention and treatment method for fundamentally overcoming heat stroke. According to the application disclosed by the invention, the remarkable effect of the DNAzymeSEQ1 in prevention and treatment of the heat stroke is fully verified through a system experiment. The DNAzymeSEQ1 delivered by the TPNs carrier shows obvious liver and lung targeting in a mouse body, the fluorescence intensity is obviously higher than that of other organs, and it is ensured that the medicine accurately acts on a key injury part of heat stroke.

The invention discloses an implantable cerebral apoplexy treatment stimulator, which comprises at least two electrode parts and at least two skull nails, the at least two electrode parts are suitable for being respectively implanted into implantation holes of at least two skull, the electrode parts are connected with wires, the wires are connected with a pulse generator, each skull nail comprises a stud part and a screwing part, and the stud part is connected with the pulse generator. The stud part is suitable for being screwed into the implantation hole, the bottom of the stud part abuts against the top of the electrode part, the screwing part is connected to the top of the stud part, an operation groove is formed in the top of the screwing part, and a screw driver can be inserted into the operation groove to rotate the skull nail. The implantable cerebral apoplexy treatment stimulator is simpler in structure and more convenient to fix on the skull, the stimulation intensity can be improved, small-range lesions can be accurately targeted, stimulation is more accurate, in addition, stimulation parameters and stimulation areas can be adjusted and controlled, the implantable cerebral apoplexy treatment stimulator dynamically adapts to cerebral injury conditions of different patients, and the cerebral apoplexy treatment effect is better.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

The invention provides a vehicle-mounted mobile shelter platform for stroke. A detecting instrument, a sound and image collector, a posture adjusting device, a medicine refrigerating box and a display device are arranged in a vehicle body; the system is further provided with a medical cloud platform, and the medical cloud platform is connected with the hospital platform system, the detection instrument, the sound and image collector, the posture adjusting device and the display device through the industrial internet system. The medical cloud platform obtains the data of the detection instrument through an edge heterogeneous data conversion module, performs data protocol and format conversion and edge data cleaning, and sends the data to a structured or unstructured database; intelligent voice recognition and intelligent image recognition are carried out on the edge heterogeneous data conversion module; and the diagnosis and treatment model intelligent body outputs expert system opinions and outputs personnel operation instructions and equipment operation instructions in combination with field decisions or field decisions and remote consultation. Through edge calculation, heterogeneous data conversion and the diagnosis and treatment model agent, the success rate of stroke treatment is greatly improved, and the probability of prognosis sequelae is reduced.

The invention is suitable for the technical field of medical rescue, and provides a dynamic allocation method and system based on a cerebral apoplexy first-aid map, and the method comprises the steps: firstly obtaining the real-time position information of a target patient, then rapidly determining the information of at least one target hospital according to the real-time position information and a preset cerebral apoplexy first-aid map, and obtaining the information of the at least one target hospital; according to the real-time position information and the geographical position information, treatment path information is effectively generated, and finally the treatment path information is sent to a rescue dispatching center in time. According to the method, the stroke treatment hospital most suitable for the specific target patient can be automatically identified, the acute stroke patient in the jurisdiction is ensured to be treated in time in the shortest time by adopting the dynamic planning and optimal scheduling strategy, the emergency scheduling effect is effectively improved, and the success rate of stroke treatment is improved.

The present application belongs to the technical field of medical first aid and resource scheduling, and relates to a stroke emergency green channel pre-starting and resource scheduling method and system. The method comprises: collecting multi-modal diagnosis and treatment data of a stroke patient; calculating a patient condition comprehensive score to determine the patient condition response level; generating a pre-starting instruction corresponding to the intensity; resource time window pre-occupation; synchronously starting the preparation of thrombolysis path tasks and thrombus extraction path tasks for ischemic stroke patients; generating a personalized timing table according to the reverse whole-link task completion time, triggering priority hierarchical upgrade reminders according to the overtime length; recording the whole-process data of diagnosis and treatment according to the preset personalized timing table; and generating a quality control report. Through the innovative design of hierarchical pre-starting, double-path parallel scheduling, whole-process timing control and the like, the present application greatly shortens the stroke treatment time, significantly improves the vascular recanalization rate and the neurological functional prognosis effect of the patient.

Pharmaceutical compositions for treating an ischemic condition in a subject may include inhibitors of protein glycosylation. Methods may include administering to the subject in need thereof an effective amount an inhibitor of protein glycosylation. The administration may be effective to promote endothelial cell proliferation and angiogenesis in the subject. The subject may be in need of induced angiogenesis due to an ischemic condition caused by a stroke. Pharmaceutical compositions for inhibiting protein glycosylation in a cell may include ManN. Methods for inhibiting protein glycosylation in a cell may include administering to a cell an effective amount of ManN.

The application belongs to the technical field of heat stroke treatment, and specifically discloses application of DNAzyme in preparation of a medicine for treating heat stroke, wherein the DNAzyme is a DNAzyme for targeted regulation of ZBP1 protein expression. The application also discloses a medicine for preventing and treating heat stroke. The application has important value for fundamentally conquering the prevention and treatment method of heat stroke. The application fully verifies the remarkable efficacy of DNAzyme_SEQ_1 in the prevention and treatment of heat stroke through systematic experiments. The DNAzyme_SEQ_1 delivered by a TPNs carrier presents obvious liver and lung targeting in the mouse body, and the fluorescence intensity is obviously higher than that of other organs, thereby ensuring that the medicine precisely acts on the key damage sites of heat stroke.

The invention relates to the field of medicine, in particular to a nitrite donor-albumin coupling medicine and a preparation method and application thereof. According to the nitrite donor-albumin coupling drug disclosed by the invention, an intelligent drug delivery system with a pH response characteristic is constructed by covalently coupling a nitrite donor compound or a derivative thereof and albumin, so that the bottleneck problems of short half-life period (lt: 1h), non-specific release, poor blood-brain barrier penetrability and the like of a traditional nitrite drug are effectively solved. The coupling medicine can significantly improve cerebral ischemia reperfusion injury through vasodilation regulation and oxidation resistance, and the infarct area is significantly reduced (about 2 times). The breakthrough provides a brand new normal form for developing cerebral apoplexy treatment medicines with targeting accuracy and multi-dimensional treatment, and has important clinical transformation value.

The invention belongs to the technical field of biological medicines, and particularly relates to application of rhubarb and ackermann bacteria in preparation of an anti-cerebral apoplexy medicine. It is found for the first time that the rhubarb aqueous extract (DH) can promote growth of ackermania muciniphila (AKK) and increase production of citrulline (Cit) metabolites, and in-vivo and in-vitro experiments prove that the combination of DH and AKK can significantly relieve cerebral ischemia-reperfusion injury, improve neurological dysfunction and promote brain tissue repair, and can be used for treating cerebral ischemia-reperfusion injury, cerebral ischemia-reperfusion injury, cerebral ischemia-reperfusion injury, cerebral ischemia-reperfusion injury and cerebral ischemia-reperfusion injury. The research result not only deepens the understanding of the pathological mechanism of the cerebral apoplexy from the molecular level, but also provides a solid theoretical basis and experimental support for developing a targeted treatment strategy based on DH combined with AKK, is expected to break through the bottleneck of current cerebral apoplexy treatment, and opens up a new intervention way for the optimization of a clinical treatment scheme.

The invention belongs to the field of stroke treatment, and provides an application of a metabolite Lacc-Phe or a synthetase CNDP2 thereof as an acute ischemic stroke treatment target, and a reagent for knocking out or knocking down the expression level of CNDP2 or an inhibitor of CNDP2 can be used for treating acute ischemic stroke or cerebral ischemia reperfusion injury. According to the application, an endogenous metabolite N-lactoyl phenylalanine (Lacc-Phe) and a synthetase CNDP2 thereof are found to be obviously increased after cerebral ischemia reperfusion injury, and the endogenous metabolite N-lactoyl phenylalanine (Lacc-Phe) and the synthetase CNDP2 thereof have relatively strong correlation with a reported cerebral arterial thrombosis marker; in addition, the knockout of the CNDP2 and the inhibitor bestatin (bestatin) of the CNDP2 can protect the cerebral ischemia reperfusion injury, and the overexpression of the CNDP2 and the exogenous administration of the Lacc-Phe can aggravate the cerebral ischemia reperfusion injury, so that the CNDP2 / Lacc-Phe axis can be used as a diagnosis, treatment and prognosis target of the cerebral arterial thrombosis disease.

The rapid cooling device comprises a neck guard and a cooling assembly, the cooling assembly comprises a moving block slidably clamped on the outer side of the neck guard, a guide frame is connected to the top end of the moving block, a pair of guide grooves are formed in the inner side of the guide frame, and a pair of arc-shaped plates are symmetrically arranged at the top end of the neck guard; the inner sides of the two arc-shaped plates and the guide frame are located on the same spherical surface, a plurality of sprayers are arranged on the inner side of the guide frame, all the sprayers are connected to a control pump through pipelines, the control pump is arranged on the outer side of the moving block, and a uniform assembly is arranged on the inner side of the guide frame; the cooling assembly and the uniformizing assembly can jointly cool the head of a patient, a rolling wheel can roll along the outer side of the head of the patient in the sliding process of a guide frame, low-temperature alcohol can be more evenly smeared on a pressing film on the outer side of the head of the patient, the cooling effect of the head of the patient is guaranteed, and meanwhile the skin of the head of the patient is prevented from being frostbitten.

The invention relates to a cerebral apoplexy treatment time window prolonging agent, application of the cerebral apoplexy treatment time window prolonging agent and a cerebral apoplexy thrombolysis kit, and the cerebral apoplexy treatment time window prolonging agent comprises a protein PAI-1 targeting inhibitor, the compound is used for being specifically combined with a plasminogen activator inhibitor PAI-1 released by activated platelets in a cerebral apoplexy thrombus area so as to inhibit the fibrinolytic inhibitory activity of the PAI-1. The invention has the beneficial effects that endogenous fibrinolysis is activated in a safe and effective way, the sharp contradiction between timeliness and safety in the prior art is directly solved, and the medicine is expected to be used as a safe early intervention medicine and provides new treatment possibility for a large number of patients who miss initial treatment opportunities. By means of the exquisite unlocking mechanism, the cerebral apoplexy treatment time window is delayed to 6 h, and precious time is gained for cerebral apoplexy treatment subsequently.

The invention relates to the technical field of medicines, in particular to an N-arylindole derivative and application thereof in preparation of a medicine for resisting cerebral arterial thrombosis. The invention relates to an N-arylindole derivative. The N-arylindole derivative is a compound as shown in a formula I, a pharmaceutically acceptable salt and an optical active body or racemate thereof, and a diastereoisomer thereof, by deeply exploring the regulation mechanism of the cerebral arterial thrombosis, potential therapeutic targets are defined, and a new research direction is provided for developing the medicine for effectively treating the cerebral arterial thrombosis. The research further enriches the structure type of the small molecule inhibitor for resisting cerebral ischemic stroke, lays a foundation for the biological activity test of subsequent monomeric compounds, not only provides an active lead compound for the development of new drugs, but also provides theoretical support for the deep research and development of the GluN2B-NMDAR antagonist in the field of cerebral stroke treatment.

This invention provides a drug delivery system and its application based on brain microvascular endothelial cells, comprising stimulated brain microvascular endothelial cells, wherein the stimulation is performed by culturing in a culture system containing supernatant of brain microvascular endothelial cells cultured under glucose and oxygen deprivation. This invention solves the problems of targeting and timeliness in treating blood-brain barrier damage after ischemic stroke under current technologies. It can regulate the BBB while supporting its function and structure, maintaining and repairing BBB function after reperfusion, thus improving the prognosis of stroke treatment. The cell preparations in this invention are widely available and easily obtained, and can rapidly repair the blood-brain barrier. Furthermore, the cell preparations in this invention can target ischemic brain sites and can be administered via simple intravenous injection, facilitating clinical operation.

An implantable cerebral apoplexy treatment stimulation device disclosed by the present invention comprises a skull nail and a conductive part, the skull nail comprises a stud part, a screwing part and an electrode part, the stud part is suitable for being screwed into an implantation hole, the screwing part is connected to the top of the stud part, the electrode part is connected to the bottom of the stud part, a mounting hole is formed in the skull nail, and the conductive part is arranged in the mounting hole. The outer surface of the stud part and the outer surface of the screwing part are electric insulation surfaces, the bottom surface of the mounting hole forms a first conductive surface, the bottom surface of the conductive part is attached to the first conductive surface, the conductive part is connected with a wire, and the wire is used for being connected with a pulse generator. The device is simple in structure and more convenient to fix on the skull, the problem that current is prone to leakage can be solved, the stimulation intensity can be improved, small-range lesions can be accurately targeted, stimulation is more accurate, stimulation parameters and stimulation areas can be adjusted and controlled, the device dynamically adapts to brain injury conditions of different patients, and the stroke treatment effect is better.

The application provides a construction method of an acute low-perfusion animal model and application thereof, and relates to the technical field of biomedicine. The construction method of the acute low-perfusion animal model of the application is aimed at brain capillary endothelial cells, and the animal model constructed is globally and durably low-perfused in brain microvessels, and the animal model has no infection or death risk and low cost. The animal model constructed by the application has important significance for researching the molecular mechanism of central nervous system injury caused by acute cerebral ischemia and developing a stroke treatment method.

The present application provides a temperature-sensitive hydrogel system for intranasal delivery of mesenchymal stem cells and application, which comprises a poloxamer hydrogel as a carrier and mesenchymal stem cells loaded on the carrier; the poloxamer hydrogel as a carrier comprises poloxamer 407 and poloxamer 188, and further comprises at least one of epidermal growth factor and fibroblast growth factor. The present application solves the problems of low efficiency of mesenchymal stem cells into the brain and poor survival ability of mesenchymal stem cells in the nasal cavity in the treatment of ischemic stroke under the current technology, improves the accumulation and activity of mesenchymal stem cells in the lesion site, and improves the prognosis of stroke treatment. The cell preparation in the present application can target the brain ischemic site, and can be administered by non-invasive intranasal administration, avoiding the risk of secondary trauma caused by invasive administration.

This invention belongs to the field of biomedical technology and discloses a methylene blue-fingolimod prodrug based on hypochlorous acid activation, its preparation method, and its application. Fingolimod and methylene blue, which has hypochlorous acid scavenging and neuroprotective functions, are bonded together via a hypochlorous acid-sensitive thioether bridge. This design cleverly utilizes the abnormally high concentration of hypochlorous acid within the lesion as "molecular scissors," achieving precise activation of the prodrug at the target site and synergistic release of both drugs. This not only endows fingolimod with targeted noise reduction and enhanced efficacy but also simultaneously implements a combined attack of "detoxification" and "anti-inflammation," thereby more thoroughly breaking the damage cascade and providing a novel synergistic solution for stroke treatment.